Abstract
Purpose
In patients with hypothyroidism, levothyroxine (LT4) is the treatment of choice, and tablets are the most commonly prescribed formulation. Despite multiple scenarios being reported in the literature with impaired tablet absorption and likely missed TSH targets, it is yet unclear what the implications are for clinical practice and the role of liquid solution (LS) and soft gel (SG) formulations. We have thus conducted a narrative review evaluating the prevalence within the general population of gastrointestinal disorders impacting tablet LT4 absorption.
Methods
PubMed and Google Scholar were searched until December 2019 for systematic reviews and meta-analyses on the topic. If they could not be retrieved, other types of manuscripts were searched.
Results
Lactose malabsorption and Helicobacter pylori infection represented the most common disorders, with a global prevalence of 68% and 48%, respectively. The prevalence of other conditions, including autoimmune gastritis, bariatric surgery, celiac disease, gastroparesis, giardiasis, liver cirrhosis, or ulcerative colitis, was lower than 20%. Data at regional and country levels were found to be heterogeneous, but at least one in five patients was diagnosed with one disorder.
Conclusions
The worldwide prevalence of gastrointestinal disorders associated with tablet LT4 malabsorption, including lactose malabsorption and Helicobacter pylori infection, is high. Interactions with drugs or food can further increase this risk. Considering that all studies investigating the impact of switching patients from tablet to LS or SG found an improved thyroid balance, the latter formulations should be considered as first-line therapy for managing hypothyroidism.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References
S.H. Pearce, G. Brabant, L.H. Duntas, F. Monzani, R.P. Peeters, S. Razvi, J.L. Wemeau, 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2, 215–228 (2013)
L. Chaker, A.C. Bianco, J. Jonklaas, R.P. Peeters, Hypothyroidism. Lancet 390, 1550–1562 (2017)
P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J.H. Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301–316 (2018)
B. Biondi, D.S. Cooper, Thyroid hormone therapy for hypothyroidism. Endocrine 66, 18–26 (2019)
N. Rodondi, W.P. den Elzen, D.C. Bauer, A.R. Cappola, S. Razvi, J.P. Walsh, B.O. Asvold, G. Iervasi, M. Imaizumi, T.H. Collet, A. Bremner, P. Maisonneuve, J.A. Sgarbi, K.T. Khaw, M.P. Vanderpump, A.B. Newman, J. Cornuz, J.A. Franklyn, R.G. Westendorp, E. Vittinghoff, J. Gussekloo, Thyroid studies collaboration: subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304, 1365–1374 (2010)
E.K. Alexander, E.N. Pearce, G.A. Brent, R.S. Brown, H. Chen, C. Dosiou, W.A. Grobman, P. Laurberg, J.H. Lazarus, S.J. Mandel, R.P. Peeters, S. Sullivan, 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27, 315–389 (2017)
Z. Shan, W. Teng, Thyroid hormone therapy of hypothyroidism in pregnancy. Endocrine 66, 35–42 (2019)
N.J. McGriff, G. Csako, L. Gourgiotis, C.G. Lori, F. Pucino, N.J. Sarlis, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med. 34, 554–564 (2002)
J. Lazarus, R.S. Brown, C. Daumerie, A. Hubalewska-Dydejczyk, R. Negro, B. Vaidya, 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur. Thyroid J. 3, 76–94 (2014)
J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, American Thyroid Association Task Force on thyroid hormone replacement: guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 24, 1670–1751 (2014)
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)
G. Grani, V. Ramundo, A. Verrienti, M. Sponziello, C. Durante, Thyroid hormone therapy in differentiated thyroid cancer. Endocrine 66, 43–50 (2019)
C. Virili, P. Trimboli, M. Centanni, Novel thyroxine formulations: a further step toward precision medicine. Endocrine 66, 87–94 (2019)
M. Skelin, T. Lucijanić, D. Amidžić Klarić, A. Rešić, M. Bakula, A.M. Liberati-Čizmek, H. Gharib, D. Rahelić, Factors affecting gastrointestinal absorption of levothyroxine: a review. Clin. Ther. 39, 378–403 (2017)
J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on hypothyroidism in adults: Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22, 1200–1235 (2012)
C. Virili, A. Antonelli, M.G. Santaguida, S. Benvenga, M. Centanni, Gastrointestinal malabsorption of thyroxine. Endocr. Rev. 40, 118–136 (2019)
S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249–253 (1995)
M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, E1454–E1458 (2014)
M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)
C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–E422 (2012)
N. Bolk, T.J. Visser, A. Kalsbeek, R.T. van Domburg, A. Berghout, Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Clin. Endocrinol. 66, 43–48 (2007)
G. Fiorini, D. Ribichini, R. Pasquali, D. Vaira, In vivo dissolution of levothyroxine soft gel capsules. Intern. Emerg. Med. 11, 1151–1152 (2016)
S. Benvenga, A. Carlé, Levothyroxine formulations: pharmacological and clinical implications of generic substitution. Adv. Ther. 36, 59–71 (2019)
I. Laurent, S. Tang, M. Astère, K.R. Wang, S. Deng, L. Xiao, Q.F. Li, Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine 61, 28–35 (2018)
C. Virili, L. Giovanella, P. Fallahi, A. Antonelli, M.G. Santaguida, M. Centanni, P. Trimboli, Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 9, 10 (2018)
C.L. Storhaug, S.K. Fosse, L.T. Fadnes, Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2, 738–746 (2017)
J.K.Y. Hooi, W.Y. Lai, W.K. Ng, M.M.Y. Suen, F.E. Underwood, D. Tanyingoh, P. Malfertheiner, D.Y. Graham, V.W.S. Wong, J.C.Y. Wu, F.K.L. Chan, J.J.Y. Sung, G.G. Kaplan, S.C. Ng, Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153, 420–429 (2017)
P. Singh, A. Arora, T.A. Strand, D.A. Leffler, C. Catassi, P.H. Green, C.P. Kelly, V. Ahuja, G.K. Makharia, Global prevalence of celiac disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16, 823–836 (2018)
S.C. Ng, H.Y. Shi, N. Hamidi, F.E. Underwood, W. Tang, E.I. Benchimol, R. Panaccione, S. Ghosh, J.C.Y. Wu, F.K.L. Chan, J.J.Y. Sung, G.G. Kaplan, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018)
The International Federation for the Surgery of Obesity and Metabolic Disorders. Fourth IFSO Global Registry Report 2018. https://www.ifso.com/pdf/4th-ifso-global-registry-report-last-2018.pdf. Accessed 10 Oct 2019
World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 10 Oct 2019
E.M. Wolf, W. Plieschnegger, M. Geppert, B. Wigginghaus, G.M. Höss, A. Eherer, N.I. Schneider, A. Hauer, P. Rehak, M. Vieth, C. Langner, Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? data from a cross-sectional Central European multicentre study. Dig. Liver Dis. 46, 412–418 (2014)
I. Coati, M. Fassan, F. Farinati, D.Y. Graham, R.M. Genta, M. Rugge, Autoimmune gastritis: pathologist’s viewpoint. World J. Gastroenterol. 21, 12179–12189 (2015)
T. Notsu, K. Adachi, T. Mishiro, H. Fujihara, T. Toda, S. Takaki, Y. Kinoshita, Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan. Intern. Med. 58, 1817–1823 (2019)
M. Camilleri, V. Chedid, A.C. Ford, K. Haruma, M. Horowitz, K.L. Jones, P.A. Low, S.Y. Park, H.P. Parkman, V. Stanghellini, Gastroparesis. Nat. Rev. Dis. Prim. 4, 41 (2018)
S.M. Cacciò, H. Sprong, in Epidemiology of giardiasis in humans. ed. by H.D. Luján, S. Svärd. Giardia (Springer, Vienna. 2011) https://doi.org/10.1007/978-3-7091-0198-8_2.
H.H. Dib, S.Q. Lu, S.F. Wen, Prevalence of Giardia lamblia with or without diarrhea in South East, South East Asia and the Far East. Parasitol. Res. 103, 239–251 (2008)
J. Xiao, F. Wang, N.K. Wong, J. He, R. Zhang, R. Sun, Y. Xu, Y. Liu, W. Li, K. Koike, W. He, H. You, Y. Miao, X. Liu, M. Meng, B. Gao, H. Wang, C. Li, Global liver disease burdens and research trends: analysis from a Chinese perspective. J. Hepatol. 71, 212–221 (2019)
Z. Hepp, M.J. Lage, R. Espaillat, V.V. Gossain, The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US. J. Med. Econ. 21, 912–919 (2018)
B. Misselwitz, M. Butter, K. Verbeke, M.R. Fox, Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Gut 68, 2080–2091 (2019)
D.L. Swagerty Jr, A.D. Walling, R.M. Klein, Lactose intolerance. Am. Fam. Physician 65, 1845–1850 (2002)
M. Asik, F. Gunes, E. Binnetoglu, M. Eroglu, N. Bozkurt, H. Sen, E. Akbal, C. Bakar, Y. Beyazit, K. Ukinc, Decrease in TSH levels after lactose restriction in Hashimoto’s thyroiditis patients with lactose intolerance. Endocrine 46, 279–284 (2014)
L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best. Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)
P. Usai-Satta, M. Scarpa, F. Oppia, F. Cabras, Lactose malabsorption and intolerance: what should be the best clinical management? World J. Gastrointest. Pharmacol. Ther. 3, 29–33 (2012)
D. Festi, R. Schiumerini, C. Birtolo, L. Marzi, L. Montrone, E. Scaioli, A.R. Di Biase, A. Colecchia, Gut microbiota and its pathophysiology in disease paradigms. Dig. Dis. 29, 518–524 (2011)
G. Certad, E. Viscogliosi, M. Chabé, S.M. Cacciò, Pathogenic mechanisms of cryptosporidium and giardia. Trends Parasitol. 33, 561–576 (2017)
D. Pabla, F. Akhlaghi, H. Zia, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 72, 105–110 (2009)
E. Lahner, R.M. Zagari, A. Zullo, A. Di Sabatino, A. Meggio, P. Cesaro, M.V. Lenti, B. Annibale, G.R. Corazza, Chronic atrophic gastritis: natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig. Liver Dis. 51, 1621–1632 (2019)
B. Lebwohl, D.S. Sanders, P.H.R. Green, Coeliac disease. Lancet 391, 70–81 (2018)
S. Benvenga, G. Capodicasa, S. Perelli, S.M. Ferrari, P. Fallahi, A. Antonelli, Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front. Endocrinol. 9, 150 (2018)
C. Virili, I. Stramazzo, M.G. Santaguida, G. Bruno, N. Brusca, S. Capriello, M. Cellini, C. Severi, L. Gargano, M. Centanni, Ulcerative colitis as a novel cause of increased need for levothyroxine. Front. Endocrinol. 10, 233 (2019)
P. Fallahi, S.M. Ferrari, I. Ruffilli, F. Ragusa, M. Biricotti, G. Materazzi, P. Miccoli, A. Antonelli, Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. Expert Opin. Drug Deliv. 14, 647–655 (2017)
M.G. Santaguida, C. Virili, S.C. Del Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51–57 (2015)
C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54, 3–14 (2016)
F. Othman, T.R. Card, C.J. Crooks, Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol. Drug Saf. 25, 1079–1087 (2016)
A. Pottegård, A. Broe, J. Hallas, O.B. de Muckadell, A.T. Lassen, A.B. Lødrup, Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther. Adv. Gastroenterol. 9, 671–678 (2016)
Ó.Ö. Hálfdánarson, A. Pottegård, E.S. Björnsson, S.H. Lund, M.H. Ogmundsdottir, E. Steingrímsson, H.M. Ogmundsdottir, H. Zoega, Proton-pump inhibitors among adults: a nationwide drug-utilization study. Ther. Adv. Gastroenterol. 11, 1756284818777943 (2018)
P. Tuppin, S. Rivière, D. Deutsch, C. Gastaldi-Menager, J.M. Sabaté, Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants. Ther. Adv. Gastroenterol. 12, 1756284819853790 (2019)
E.D. Kantor, C.D. Rehm, M. Du, E. White, E.L. Giovannucci, Trends in dietary supplement use among US adults from 1999-2012. JAMA 316, 1464–1474 (2016)
World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. 2016. https://apps.who.int/iris/bitstream/handle/10665/250796/9789241549912-eng.pdf;jsessionid=44005E34839EDE838D758B02A4FBD272?sequence=1. Accessed 10 Oct 2019
D. Ribichini, G. Fiorini, A. Repaci, V. Castelli, L. Gatta, D. Vaira, R. Pasquali, Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine 57, 394–401 (2017)
R. Negro, R. Valcavi, D. Agrimi, K.A. Toulis, Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients. Endocr. Pract. 20, 901–906 (2014)
C. Cappelli, I. Pirola, E. Gandossi, C. Casella, D. Lombardi, B. Agosti, F. Marini, A. Delbarba, M. Castellano, TSH variability of patients affected by differentiated thyroid cancer treated with levothyroxine liquid solution or tablet form. Int. J. Endocrinol. 2017, 7053959 (2017)
P. Fallahi, S.M. Ferrari, G. Materazzi, F. Ragusa, I. Ruffilli, A. Patrizio, P. Miccoli, A. Antonelli, Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): a prospective study. Laryngoscope Investig. Otolaryngol. 3, 405–408 (2018)
R. Ferrara, V. Ientile, V. Arcoraci, C. Ferrajolo, C. Piccinni, A. Fontana, S. Benvenga, G. Trifirò, Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015. Endocrine 58, 143–152 (2017)
D. Gullo, A. Latina, F. Frasca, S. Squatrito, A. Belfiore, R. Vigneri, Seasonal variations in TSH serum levels in athyreotic patients under L-thyroxine replacement monotherapy. Clin. Endocrinol. 87, 207–215 (2017)
D. Wang, X. Cheng, S. Yu, L. Qiu, X. Lian, X. Guo, Y. Hu, I. Lu, G. Yang, H. Liu, Data mining: seasonal and temperature fluctuations in thyroid-stimulating hormone. Clin. Biochem. 60, 59–63 (2018)
D. Santi, G. Spaggiari, G. Brigante, M. Setti, S. Tagliavini, T. Trenti, M. Simoni, Semi-annual seasonal pattern of serum thyrotropin in adults. Sci. Rep. 9, 10786 (2019)
G. Grani, D. Tumino, V. Ramundo, L. Ciotti, C. Lomonaco, M. Armillotta, R. Falcone, P. Lucia, M. Maranghi, S. Filetti, C. Durante, Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. J. Endocrinol. Investig. 42, 1485–1490 (2019)
Funding
This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
Author information
Authors and Affiliations
Contributions
M.C. and P.T. conceived the review. M.C. and P.T. performed database search and drafted the manuscript. All authors read, provided feedback, and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This narrative review was in accordance with the principles of the Declaration of Helsinki. Analyses were performed on data extracted from published papers.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Castellana, M., Castellana, C., Giovanella, L. et al. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. Endocrine 67, 281–290 (2020). https://doi.org/10.1007/s12020-019-02185-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-02185-4